✨ Free AI Report
Clearside Biomedical, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Clearside Biomedical, Inc.
Research Preview

Clearside Biomedical, Inc.: Business Overview, Financials & Competitive Analysis

Clearside Biomedical is a biopharmaceutical company developing therapies for back-of-the-eye diseases using its proprietary suprachoroidal space (SCS) injection platform and SCS Microinjector. The company has commerci...

Analyst-debate audio for Clearside Biomedical, Inc.

AskCyborg analysts argue the bull and bear cases for Clearside Biomedical, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Clearside Biomedical, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
2/ 10Critical

Cyborg Score thesis

Clearside's suprachoroidal platform and Phase 3-ready wet AMD program have acquisition appeal, but current financial distress and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest Clearside Biomedical, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Clearside Biomedical, Inc. Overview

Pro stress-test →

Clearside Biomedical is a biopharmaceutical company developing therapies for back-of-the-eye diseases using its proprietary suprachoroidal space (SCS) injection platform and SCS Microinjector. The company has commercialized XIPERE® (triamcinolone acetonide) through Bausch + Lomb for uveitic macular edema and is advancing CLS-AX (axitinib injectable suspension), a Phase 3-ready program for wet age-related macular degeneration, while operating five suprachoroidal licensing partnerships.

Strategic Profile

Pro stress-test →

Clearside pioneered suprachoroidal delivery as an alternative route to treat posterior segment eye diseases, enabling targeted compartmentalized delivery with potentially fewer systemic side effects. The company operates a hybrid "Product + Platform" model: generating royalty revenue from licensing its SCS Microinjector technology to pharma and gene-therapy partners while building an internal pipeline of small-molecule assets. However, the company filed voluntary Chapter 11 bankruptcy in November 2025 to pursue a strategic sale of its platform and pipeline assets.

Competitive Landscape

Pro stress-test →

Clearside competes in retinal disease treatment against larger ophthalmology players including Regeneron (wet AMD anti-VEGF therapy Eylea), Novartis (Beovu and gene therapy portfolio), Roche/Genentech (wet AMD biologics), AbbVie (retinal gene therapy through REGENXBIO partnership), and smaller specialized players like Aura Biosciences (ocular tumor gene therapy). Clearside's competitive differentiation centers on its proprietary suprachoroidal delivery mechanism, which enables targeted posterior-segment drug exposure with a simple office-based procedure. However, competitors' scale, commercial infrastructure, and established wet AMD market share present significant competitive headwinds.

Industry Context

Clearside Biomedical, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2011 · Headquarters: Alpharetta, Georgia, US · Employees: 10–50 · Revenue: Estimated $5M–$10M (2024); primarily royalty-based from XIPERE and licensing partnerships

What the analysts stress-tested

The top findings that survived the multi-agent debate for Clearside Biomedical, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Clearside Biomedical, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Regeneron PharmaceuticalsLeading anti-VEGF therapy developer for wet AMD and retinal disease→Novartis AGAnti-VEGF market leader with Beovu-approved wet AMD treatment and Eylea portfolio→Allergan (AbbVie portfolio)Ophthalmic therapies and anti-VEGF agent portfolio competitor→

Compare Clearside Biomedical, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Clearside Biomedical, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Clearside Biomedical, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Clearside Biomedical, Inc. and its top competitor on Cyborg Score”
“What did Clearside Biomedical, Inc. do this quarter?”
“Is Clearside Biomedical, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Clearside Biomedical, Inc. do?+
Clearside Biomedical is a biopharmaceutical company developing therapies for back-of-the-eye diseases using its proprietary suprachoroidal space (SCS) injection platform and SCS Microinjector. The company has commerci...
What is Clearside Biomedical, Inc.'s Cyborg Score?+
Clearside Biomedical, Inc. has a Cyborg Score of 2/10 (Critical). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Clearside Biomedical, Inc.'s main competitors?+
Named competitors include Regeneron Pharmaceuticals, Novartis AG, Allergan (AbbVie portfolio). The full competitive landscape is in the AskCyborg report.
How can I get the full Clearside Biomedical, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Clearside Biomedical, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Clearside Biomedical, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.